(1) Subjects who are infected with novel coronavirus (hereinafter, SARS-CoV-2) or have a history of infection (based on the interview with subjects legally acceptable representatives)(2) Subjects who have had close contact with a person infected with SARS-CoV-2 (excluding those whose infection was denied by a test) (based on the interview with subjects legally acceptable representatives)(3) Subjects who have received a COVID-19 vaccine (including unapproved vaccines) in the past(4) Subjects with a known history of anaphylaxis due to KD-414 or its ingredient (thimerosal).(5) Female subjects who are pregnant, may be pregnant, are desiring to become pregnant before completion of the follow-up test, or are breast-feeding.

(1) Subjects who are infected with novel coronavirus (hereinafter, SARS-CoV-2) or have a history of infection (based on the interview with subjects legally acceptable representatives)(2) Subjects who have had close contact with a person infected with SARS-CoV-2 (excluding those whose infection was denied by a test) (based on the interview with subjects legally acceptable representatives)(3) Subjects who have received a COVID-19 vaccine (including unapproved vaccines) in the past(4) Subjects with a known history of anaphylaxis due to KD-414 or its ingredient (thimerosal).(5) Female subjects who are pregnant, may be pregnant, are desiring to become pregnant before completion of the follow-up test, or are breast-feeding.